Celgene Corp. Target of Unusually Large Options Trading (CELG)
Shares of Celgene Corp. (NASDAQ:CELG) was the recipient of unusually large options trading activity on Monday. Stock traders bought 13,496 call options on the stock, Analyst Ratings Network reports. This is an increase of 163% compared to the typical volume of 5,139 call options.
Several analysts have recently commented on the stock. Analysts at Leerink Swann raised their price target on shares of Celgene Corp. (NASDAQ:CELG) from $165.00 to $177.00 in a research note to investors on Wednesday, September 25th. They now have an “outperform” rating on the stock. Separately, analysts at TheStreet reiterated a “buy” rating on shares of Celgene Corp. (NASDAQ:CELG) in a research note to investors on Tuesday, September 24th. Finally, analysts at Goldman Sachs Group Inc. raised their price target on shares of Celgene Corp. (NASDAQ:CELG) from $113.00 to $129.00 in a research note to investors on Wednesday, September 18th. Six investment analysts have rated the stock with a hold rating and twenty-five have assigned a buy rating to the company. Celgene Corp. has an average rating of “Buy” and a consensus target price of $142.48.
Celgene Corp. (NASDAQ:CELG) traded down 0.31% on Monday, hitting $154.137. 3,613,315 shares of the company’s stock traded hands. Celgene Corp. has a one year low of $71.23 and a one year high of $154.99. The stock’s 50-day moving average is $143.3 and its 200-day moving average is $128.4. The company has a market cap of $63.393 billion and a P/E ratio of 43.24.
Celgene Corp. (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, July 25th. The company reported $1.52 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.44 by $0.08. The company had revenue of $1.56 billion for the quarter, compared to the consensus estimate of $1.54 billion. During the same quarter in the previous year, the company posted $1.22 earnings per share. The company’s revenue for the quarter was up 17.0% on a year-over-year basis. On average, analysts predict that Celgene Corp. will post $5.97 earnings per share for the current fiscal year.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.